Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR

Hudson Bay Capital Management LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 107,678 shares of the biopharmaceutical company’s stock, valued at approximately $6,127,000. Hudson Bay Capital Management LP owned about 0.53% of Nektar Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the second quarter worth approximately $65,000. Integrated Wealth Concepts LLC bought a new position in shares of Nektar Therapeutics in the first quarter valued at $68,000. Compass Wealth Management LLC bought a new position in shares of Nektar Therapeutics in the third quarter valued at $88,000. Finally, Bessemer Group Inc. lifted its position in shares of Nektar Therapeutics by 1,741.2% during the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,480 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.

Key Stories Impacting Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Rezpegaldesleukin Phase 2b data accepted for two oral presentations at the 2026 American Academy of Dermatology meeting — raises scientific visibility for NKTR’s lead autoimmune program and could boost investor confidence if the presented data look favorable. Article Title
• Positive Sentiment: Broker consensus/price-target commentary is above current levels (reported average target ~$133), indicating upside in analyst models even as short-term uncertainty persists. Article Title
• Neutral Sentiment: HC Wainwright issued mixed estimate revisions (cut some near-term FY2026/FY2027 EPS estimates but raised other quarter/year figures and kept a Buy rating with a $165 target) — suggests analysts are reworking timelines rather than abandoning the bull case.
• Neutral Sentiment: TD Cowen initiated coverage (coverage initiation can increase attention/liquidity; read the initiation note for stance and target). Article Title
• Neutral Sentiment: Media commentary lists Nektar as a potential acquisition candidate — positive if it fuels takeover speculation, but purely speculative until firm bids surface. Article Title
• Negative Sentiment: Multiple securities class-action lawsuits have been filed and several law firms are soliciting lead plaintiffs (class period generally Feb 26, 2025 – Dec 15, 2025); a May 5, 2026 lead-plaintiff deadline is being emphasized — this legal uncertainty creates near-term downside risk and can pressure valuation. Article Title
• Negative Sentiment: Investor alerts highlight alleged issues around clinical enrollment/compliance for REZOLVE‑AA — if regulators or trial monitors identify problems, that could materially delay programs and hurt sentiment. Article Title

Insider Buying and Selling at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares of the company’s stock, valued at $5,510,697. The trade was a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the completion of the transaction, the insider owned 21,354 shares in the company, valued at $761,697.18. This represents a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,470 shares of company stock worth $181,955 over the last three months. 5.25% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NKTR. Piper Sandler reissued an “overweight” rating and set a $105.00 price objective on shares of Nektar Therapeutics in a research note on Monday, January 26th. TD Cowen assumed coverage on Nektar Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. HC Wainwright upped their target price on Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Citigroup increased their price target on Nektar Therapeutics from $102.00 to $123.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Finally, B. Riley Financial reissued a “buy” rating and issued a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research note on Monday, February 23rd. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.43.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $72.22 on Friday. The firm’s 50 day moving average price is $56.61 and its two-hundred day moving average price is $54.59. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $77.00. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -7.08 and a beta of 1.17.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. The company had revenue of $21.81 million during the quarter, compared to analyst estimates of $10.44 million. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%. On average, research analysts forecast that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.